BioNTech SE (BNTX)
85.68
+0.64
(+0.75%)
USD |
NASDAQ |
Nov 13, 16:00
85.60
-0.08
(-0.09%)
After-Hours: 19:59
BioNTech Gross Profit Margin (Quarterly) : 71.11% for Sept. 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 71.11% |
| June 30, 2026 | -169.3% |
| March 31, 2026 | -63.17% |
| December 31, 2025 | 63.27% |
| September 30, 2025 | 90.24% |
| June 30, 2025 | 70.71% |
| March 31, 2025 | 54.16% |
| December 31, 2024 | 79.54% |
| September 30, 2024 | 85.63% |
| June 30, 2024 | 53.54% |
| March 31, 2024 | 68.50% |
| December 31, 2023 | 87.89% |
| September 30, 2023 | 81.93% |
| June 30, 2023 | 2.86% |
| Date | Value |
|---|---|
| March 31, 2023 | 92.48% |
| December 31, 2022 | 95.71% |
| September 30, 2022 | 78.25% |
| June 30, 2022 | 76.08% |
| March 31, 2022 | 79.70% |
| December 31, 2021 | 89.46% |
| September 30, 2021 | 80.10% |
| June 30, 2021 | 83.35% |
| March 31, 2021 | 88.62% |
| December 31, 2020 | 85.17% |
| September 30, 2020 | 77.38% |
| June 30, 2020 | 66.22% |
| March 31, 2020 | 49.21% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| Moderna, Inc. | 70.60% |
| Mereo BioPharma Group Plc | 49.12% |
| NuCana Plc | -- |
| Immatics NV | 0.00% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -8.09% |
| Return on Assets | -7.08% |
| Return on Invested Capital | -7.95% |
| Profit Margin (Quarterly) | 14.31% |
| Operating Margin (Quarterly) | 12.89% |
| Return on Net Operating Assets | -39.36% |